Highlights Grifols, S.A.

Stocks

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME Other stock markets 16:35:14 10/06/2026 BST			5-day change	1st Jan Change
8.942 ^EUR	+0.13%		-0.31%	-16.43%

06-09	European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading	MT
06-08	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT

Highlights

05-26	Grifols' Insatiable Appetite
05-08	Grifols: FCFs didn't impress; rebuilding trust isn't going to be easy
05-08	Grifols Q1 Adjusted Profit Rises, Revenue Falls	MT
05-07	Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Grifols on track to deliver 2026 objectives	RE
04-16	Grifols receives FDA approval for its malaria blood screening assay	RE
04-06	AlphaValue/Baader Europe Lowers Grifols Forecasts Amid Lack of FY26 Sales Growth Guidance	MT
04-02	Grifols Faces New Health Canada Conditions After Inspection Deficiencies	MT
04-02	Spanish stocks - Factors to watch on April 2	RE
03-27	Grifols: IPO plans for a subsidiary don't smell right
03-25	Grifols to list plasma unit to tackle massive debt pile
03-25	Grifols approves IPO for its US biopharmaceutical business	RE
03-25	Grifols Plans IPO of Minority Stake in US Biopharmaceutical Business	MT
03-25	Grifols Plans IPO of Minority Stake in US Biopharmaceutical Business	MT
03-24	Grifols to Evaluate Potential IPO of US Biopharma Business	MT
03-24	Grifols - Board has approved IPO on U.S. stock market of a portion of shares of Grifols' U.S. biopharma business	RE
03-24	Grifols approves IPO of its US biopharma business	RE
03-24	Grifols says it has decided to initiate a process to evaluate a potential US IPO of a portion of shares of its subsidiary and parent of U.S. biopharma business	RE
03-24	Grifols, S.A. Announces Evaluation of Potential IPO for U.S. Biopharma Business	CI
02-27	Grifols Expects 25% Increase in 2026 EBITDA as Profitability Takes Priority	RE
02-26	Grifols, S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-26	Grifols sees core earnings rising by a quarter as it prioritises profitability	RE
02-26	Grifols doubles net profit in 2025, driven by revenues	RE
02-26	Grifols sees 2026 adjusted EBITDA margin above 25%	RE
12-19	Grifols Wins US FDA Approval for Rare Blood Disorder Drug Fesilty	MT